Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response

(2012) Y. Godet et al.   CLINICAL CANCER RESEARCH

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

(2012) Benjamin Weide et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune parameters affecting the efficacy of chemotherapeutic regimens

(2011) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Development and dynamics of robust T-cell responses to CML under imatinib treatment

(2008) C. I-U. Chen et al.   BLOOD

Multiple roles for CD4+T cells in anti-tumor immune responses

(2008) Richard Kennedy et al.   IMMUNOLOGICAL REVIEWS